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Abstract
Primary myelofibrosis (PMF) is a Ph-negative myeloproliferative neoplasm (MPN), 
characterized by advanced bone marrow fibrosis and extramedullary haematopoie-
sis. The bone marrow fibrosis results from excessive proliferation of fibroblasts that 
are influenced by several cytokines in the microenvironment, of which transforming 
growth factor-β (TGF-β) is the most important. Micromechanics related to the niche 
has not yet been elucidated. In this study, we hypothesized that mechanical stress 
modulates TGF-β signalling leading to further activation and subsequent proliferation 
and invasion of bone marrow fibroblasts, thus showing the important role of micro-
mechanics in the development and progression of PMF, both in the bone marrow and 
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1  | INTRODUC TION
Primary myelofibrosis (PMF) is a Ph-negative myeloproliferative 
neoplasm (MPN), characterized by advanced bone marrow fibrosis 
and extramedullary haematopoiesis that is most pronounced in the 
liver and spleen.[1] Among MPNs, approximately 50% of patients 
with PMF and essential thrombocythemia (ET) are JAK2 V617F pos-
itive, whereas >90% polycythemia vera (PV) patients are positive 
for this mutation.[2-4] To date, several ‘driver’ mutations have been 
identified in the pathogenesis of PMF, involving target genes such 
as JAK2, CALR and MPL, whereas less commonly involved genes in-
clude ASXL1, SRSF1 and U2AF1.[5-8] The bone marrow fibrosis re-
sults from proliferation of fibroblasts that are influenced by several 
cytokines in the microenvironment including transforming growth 
factor-β (TGF β), basic fibroblast growth factor (FGF), platelet-derived 
growth factor (PDGF) and calmodulin.[9-13] A likely source of these 
factors is the underlying malignant clone that may acquire different 
phenotypic states including megakaryocyte or monocyte differentia-
tion.[12,14,15] In support of these data, we have recently shown that 
the fibroblasts involved in this process do not derive from the malig-
nant clone but seem to represent over-stimulated normal cells.[16]
The main cytokine believed to be involved in generation of PMF-
associated fibrosis is TGF β.[17] TGF-β acts on fibroblast physiology 
by increasing synthesis of collagen, type I, III, IV and V, as well as pro-
duction of fibronectin, proteoglycans and tenascin.[18] Although the 
importance of TGF β in fibroblast proliferation was previously un-
derlined in studies of PMF, micromechanics related to the niche has 
yet been elucidated, as progression in PMF occurs in a tense niche, 
with a relatively high level of mechanical stress.[18,19] The role of 
bone marrow mechanical stress via TGF-β modulation was assessed 
by Balooch et al, with potential clinical implications.[20] Data were 
confirmed by Zhao et al[21] that have shown that bone marrow-de-
rived mesenchymal stem cells have resistance to flow shear stress 
through AMP-activated protein kinase signalling.
In the current study, we hypothesized that mechanical stress pro-
duced during PMF progression modulates TGF-β-dependent signal-
ling. TGF-β is secreted by the malignant megakaryocytes, leading to 
further activation and subsequent proliferation and invasion of bone 
marrow fibroblasts, both in the bone marrow and in distant organs. 
Thus, we demonstrate the important role of micromechanics in the 
microenvironment and the development and progression of PMF.
2  | MATERIAL S AND METHODS
2.1 | Cell cultures
Primary myelofibrosis-derived fibroblast cell lines used were iso-
lated and characterized as previously published [16] (Figure 1). All 
cells were grown in a humidified atmosphere at 37°C air, 95%; car-
bon dioxide (CO2), 5%. Cell passage and cultures were carried out 
as previously described.[22-24] All cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM), supplemented with penicillin/
streptomycin and non-essential amino acids. Hanging drops were 
used to isolate the cells from any external stimuli, and cells were fur-
ther treated in hanging drops for 4 days until spheroids were formed 
and the fibroblasts were inactivated. Re-activation of the fibroblasts 
was carried out by digesting the spheroids with trypsin and culture 
on a plastic dish. Once re-activated, proliferation and collagen type 
I and III increased. For the hanging drop experiments, classic Petri 
dishes were used, making this experiment feasible and reproducible 
in any laboratory setting. Images of the cells were obtained by in-
verted phase microscopy from activated, re-activated as well as or-
ganoids in a 30-μ dish (50 mm) using an inverted Zeiss Axio Observer 
Z1 microscope, as previously described.[25-27]
2.2 | shRNA TGFBR1 and TGFBR2 knock-down
Transforming growth factor-β receptor (TGFBR) 1 and 2 knock-down 
PMF-derived fibroblasts were obtained in collaboration with the 
Department of Oncology, the Johns Hopkins University School of 
Medicine in Baltimore, USA. Briefly, cells were plated at density of 
5 × 106 cells/plate confluence in 8 mL of DMEM with 10% FBS with 
no penicillin/streptomycin. At Day 2, cells were transfected with 
lipofectamine. The DNA mix was shRNA plasmid (9ſg) + delta8.9 
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in extramedullary sites. Using three PMF-derived fibroblast cell lines and transform-
ing growth factor-β receptor (TGFBR) 1 and 2 knock-down PMF-derived fibroblasts, 
we showed that mechanical stress does stimulate the collagen synthesis by the fibro-
blasts in patients with myelofibrosis, through the TGFBR1, which however seems to 
be activated through alternative pathways, other than TGFBR2.
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(9ſg) + VSVG (3ſg) + 800 µL Opti-MEM. Medium was changed the 
following day. Virus titre was at its highest approximately 24 hours 
after transfection. The medium was passed through a 0.45 µm filter 
unit attached to a syringe. Transduction of cells with lentivirus su-
pernatant and selection with puromycin was carried out at Day 5. 
The puromycin selection process was done using 4-4.25 µg/mL for 
PMF-derived fibroblasts and continued until all non-transduced con-
trol cells were dead. Later, living cells were transferred to T25 flasks 
and expanded before assessment of the knock-down via qPCR.
2.3 | Assessment of micromechanics on the PMF-
derived fibroblasts
Following TGFBR1 and TGFBR2 knock-down, the role of mechani-
cal pressure of the cells was assessed on three cell lines: TGFBR1 
knock-down cells, TGFBR2 knock-down and wild-type cells, used 
as negative control. Micromechanics was assessed using the 
Flexcell FX-6000 Tension System, in collaboration with the Stem 
Cell Research Unit, Biomedical Centre, School of Health Sciences, 
University of Iceland—Department of Laboratory Hematology, 
Landspitali University Hospital, Reykjavík, Iceland, as previously 
described.[28-32] Briefly, cells were cultured as described above. 
Equal number of cells were seeded on each well in a 6-well BioFlex 
plates (Flexcell International Corporation, Burlington, CA, USA) and 
grown to approximately 80% confluence. These plates were then 
transferred to a base plate of the cell stretching equipment Flexcell 
FX-5000TM Tension System (Flexcell International Corporation) in a 
humidified incubator at 37°C and 5% CO2. The cells were subjected 
to cyclic mechanical stretch with the following parameters: a stretch-
ing rate of 20% with a square signal, 0.33 Hz frequency (20 cycles/
min) and a 1:1 stretch: relaxation ratio. The cells were stretched for 6 
and 24 hours as described in the results. Control BioFlex plates were 
kept in the same incubator under static conditions as non-stretch 
controls. We compared fibroblasts obtained from myelofibrosis pa-
tients with a healthy bone marrow stroma, with the obtained data 
presented in the results section. A dashed line is used to illustrate a 
fold change of 1. Up-regulation of TGFBR1 and down-regulation of 
TGFBR2 were assessed in both primary lines (experimental groups) 
compared with normal stroma (control cells).
2.4 | DNA and RNA extraction
Total RNA was isolated using TRIzol reagent (Invitrogen), as previ-
ously described.[33-35]
2.5 | Quantitative RT-PCR (q RT-PCR) for 
mRNA expression
Quantitative RP-PCR was performed to confirm the expression of 
the collagen type I and type III expression, using TaqMan PCR tech-
nology.[36-38] For the PCR, following first-strand synthesis, 10 μL 
of RT reaction mixture was used for subsequent PCR amplification 
by adding 40 μL of PCR master mix to the same wells. The PCR reac-
tion mixture included 1X PCR buffer, 200 μmol/L of each dNTP and 
1.25 U Taq polymerase (Roche Molecular Biochemicals, Indianapolis, 
IN, USA) in a final volume of 50 μL. Amplification and real-time data 
acquisition were performed in an ABI Prism 7700 Sequence Detector 
using the following cycle conditions: initial denaturation at 95°C for 
1 minute, followed by 40 cycles of denaturation at 95°C for 12 sec-
onds, and annealing at 60°C for 1 minute. The primers used for colla-
gen I: the forward primer is 5'-CATGACCGAGACGTGTGGAAACC-3', 
and reverse primer is 5'-CATGACCGAGACGTGTGGAAACC. 
The primers used for collagen III: the forward primer is 
5'-GGATCAGGCCAGTGGAAATGTAAAGA-3', and reverse primer is 
5'-CTTGCGTGTTCGATATTCAAAGACTGTT. Cycle passing thresh-
old (Ct) was recorded and normalized to human GAPDH (hGAPDH) 
expression. Relative expression was calculated as 2Ct_FLT3-Ct_
GAPDH. PCR reactions were carried out in triplicate. All mRNA q 
RT-PCR values were normalized to β-actin, and the relative expres-
sion was calculated as 2Ct_target gene-Ct_GAPDH. PCR reactions 
were carried out in triplicate. As internal controls, we used hGAPDH 
F I G U R E  1   Isolation and 
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forward, 5′-GTGGTCTCCCTGACTTTCAACAGC-3′, and hGAPDH re-
verse, 5′-ATGAGGTCCACCACCTGCTTGCTG-3′ (149-bp amplicon).
2.6 | Western blotting
Cells were lysed in Laemmli sample buffer (Bio-Rad, Hercules, CA, 
USA) supplemented with a protease inhibitor complete EDTA-free 
(Roche). Protein concentration was measured using BCA Protein 
Assay kit (Pierce, Rockford, MA, USA). Cell lysates (50 µg) were elec-
trophoresed on 10%-20% polyacrylamide gels (Bio-Rad) and trans-
ferred to Immobilon PSQ membranes (Millipore, Bedford, MA, USA). 
The membranes were blocked with TBS containing 5% skim milk and 
0.1% Tween-20, then incubated with the primary antibody overnight, 
at 4°C. Antibodies for collagen I and collagen III were purchased 
from Abcam (Cambridge, UK). The membranes were incubated after 
washing with HRP-conjugated goat anti-rabbit IgG (Calbiochem, 
Gibbstown, NJ, USA) and analysed using enhanced chemilumines-
cence plus reagent (GE Healthcare, Buckinghamshire, UK).
2.7 | Animals and housing for the in vivo 
experiments
Athymic nude mice Crl:NU(Ncr)-Foxn1nu mice (Charles River, 
Laboratories, Wilmington, MS, USA) were used in the present study. 
The animals were housed in polysulfone type II-L open-top cages 
(Tecniplast Buguggiate, Italy) and had access to filtered tap water 
in bottles and pelleted feed (Cantacuzino Institute, Bucharest, 
Romania) ad libitum. The bedding was a standard wood chip asep-
tic bedding (Lignocel®; J. Rettenmaier & Söhne GmBH+Co. KG, 
Rosenberg, Germany). The mice were bred and kept in the Animal 
Facility of the Medfuture Research Center for Advanced Medicine, 
Iuliu Hatieganu University of Medicine and Pharmacy at a standard 
temperature of 22°C ± 2°C and a relative humidity of 55% ± 10%, 
in a 12:12-hour light:dark cycle (lights on, 7 am to 7 pm) at a light in-
tensity of 300 lx at 1 m above the floor, and were allocated into two 
groups: group A (experimental group) and group B (control group). 
The groups were randomized in different cages, and the individu-
als were numbered on the base of their tail using permanent mak-
ers (Sharpie, Oak Brook, IL, USA). All experimental protocols were 
approved by the Ethics Committee of Iuliu Hatieganu University of 
Medicine and Pharmacy and were conducted in accordance with 
the EU Directive 63/2010. Prior to the onset of the study, all ani-
mals were quarantined and left to acclimatize to the separation from 
the mice colony for 10 days. For environmental enrichment, auto-
claved braided cotton dental rolls were used (Celluron®; Hartmann, 
Heidenhelm, Germany). The study was designed and performed 
in accordance with the ARRIVE Guidelines for Reporting Animal 
Research. All animal-handling procedures were performed accord-
ing to the European and Romanian guidelines.
Group A (experimental group) mice were injected with GFP-
positive PMF-derived fibroblasts in the central venous system, 
whereas group B (control group) were injected with normal bone 
marrow-derived fibroblasts. The in vivo experiments allowed us to 
investigate whether PMF-derived fibroblasts had the potential to in-
vade hematopoietic organs following injection in the systemic blood 
flow of immunocompromised animals. One month following injec-
tion of 1 × 106 cells in the central venous system, all animals were 
sacrificed, and pathology slides were used to assess both the bone 
marrow and lung tissue using dark-field microscopy.
2.8 | Confocal microscopy
Confocal microscopy was performed on an Olympus FLUOVIEW 
FV1200 laser scanning confocal microscope (Olympus, Tokyo, 
Japan). Image acquisition was performed using the UPLSAPO 10X2 
(0.4 NA) objective. The images were obtained using channel mode 
(488 nm excitation and bright field). Other settings for the image 
acquisition were determined using the FV10-ASW 4.2 software. 
Images were processed using ImageJ.
2.9 | Transthoracic echocardiography in 
PMF patients
Routine transthoracic echocardiography (TTE) (Phillips Affinity 50G 
echograph) was used to investigate pulmonary hypertension in PMF 
patients. TTE was carried out by a certified cardiologist, experienced 
in the clinical evaluation of patients with chronic cardiopulmonary 
diseases and evaluated the right ventricle/left ventricle basal diam-
eter ratio, flattening of the interventricular septum, right ventricular 
outflow Doppler acceleration time, pulmonary artery diameter and 
inferior vena cava diameter.
2.10 | Statistical analysis
The data were analysed using two statistical software packages 
(GraphPad Prism 5.0 and R; GraphPad software, Inc, La Jolla, CA, 
USA). Initial results were assessed by using the Shapiro-Wilk test 
to determine whether the distribution was normal. The distribution 
of all the obtained data was Gaussian; thus, it was analysed using a 
parametric test (two-way ANOVA with Tukey post-test). The differ-
ences were considered significant when P value was <0.05.
3  | RESULTS
3.1 | Knock-down of TGFBR1 and TGFBR2 in PMF-
derived fibroblasts
Four shRNA candidates were selected for TGFBR1 (TRCN0000039775 
and TRCN0000039776) and TGFBR2 (TRCN0000000833 and 
TRCN0000000834). Lentiviral supernatants were subsequently 
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generated carrying 3 types of shRNA (TRCN0000000834, 
TRCN0000039775 and TRCN0000039776). These were suc-
cessfully transduced to and selected (4.5 μg/mL puromycin) for in 
PMF-derived fibroblast cells with the following constructs: pGIPZ—
scrambled shRNA, TRCN0000000834, TRCN0000039775 and 
TRCN0000039776, as shown in Figure 2A and B. The result of the 
knock-down is shown in Figure 2C that depicts a 2% agarose gel with 
TGFBR1 and TGFBR2 PCR products of the knock-down cells. pGipz 
depicts PMF-derived fibroblasts with a blank vector, A cells depict 
PMF-derived fibroblasts with TGFBR1 knock-down, and B cells de-
pict PMF-derived fibroblasts with TGFBR2 knock-down. The data 
show that we successfully integrated the shRNA and pGIPZ con-
structs in PMF-derived fibroblasts, and from a transcriptomic point, 
the knock-down for TGFBR2 was successful. Higher passage number 
can negatively impact transduction efficacy (data not shown), and the 
phenomenon observed for the TGFBR2 knock-down might be a com-
pensatory mechanism or the heterodimer nature of the receptor.[39]
3.2 | Micromechanics of PMF-derived fibroblasts
We compared fibroblasts obtained from myelofibrosis patients with 
a healthy bone marrow stroma. A dashed line is used to illustrate 
a fold change of 1. Up-regulation of TGFBR1 and down-regulation 
of TGFBR2 can be observed in both primary lines compared with 
normal stroma. This can lead to the hypothesis that myelofibrosis-
derived fibroblasts, acting as cancer-associated fibroblasts, are 
highly dependent on TGFBR1, with a possible compensatory down-
regulation of TGFBR2 (Figure 3A). As shown in Figure 3B, Western 
blotting confirmed the RT-PCR data.
The influence of mechanical stress is shown in Figure 4A (RT-
PCR data), B (Western blotting data at 6 hours) and C (Western blot-
ting data at 24 hours). Fold change was determined using the delta 
CT method. β2-microglobulin was used as housekeeping gene. We 
compared fibroblasts under tension versus control fibroblasts; thus, 
a fold change under 1 was considered as down-regulated in fibro-
blasts under tension compared with control fibroblasts and a fold 
change over 1 was considered as up-regulation in fibroblasts under 
tension compared with control fibroblasts. The dashed line is used to 
illustrate a fold change of 1. Scales differ between gene expressions 
because fold changes vary widely between them, so we considered 
that a free y-axis would be a more appropriate representation.
3.3 | Invasive potential of PMF-derived fibroblasts
After proving that micromechanics plays a role in PMF progression 
following PMF-derived fibroblast activation and increased prolif-
eration, we aimed at assessing the potential of these cells, acting 
as cancer-associated fibroblasts, to invade distant organs. Thus, 
we used nude immunocompromised mice for in vivo experiments. 
Following the injection of GFP-positive PMF-derived fibroblasts 
(green fibroblasts), as well as normal fibroblasts, acting as the control 
group, into the systemic blood flow of nude mice, we evaluated their 
invasive potential 4 weeks later. Animals were killed, and pathology 
slides were used to assess the internal organs and bone marrow of 
the mice. We identified GFP-positive cells in the lungs (Figure 5A) 
and bone marrow (Figure 5B) of the nude mice using confocal mi-
croscopy. The upper images represent the bright-field microscopy 
merged with the channel corresponding to GFP emission, and the 
lower images show only the green channel. In the right images, we 
have the experimental group (with GFP-positive cells pointed using 
an arrow), whereas in the left images we have the control group, lack-
ing any GFP-positive cell. The autofluorescence of paraffin was re-
moved using the FV10-ASW 4.2 software, but the autofluorescence 
of red blood cells was still visible.
F I G U R E  2   A, PCR analysis for the knock-down of TGFBR1. B, PCR analysis for the knock-down of TGFBR2. C, 2% agarose gel with 
TGFBR1 and TGFBR2 PCR products of the knock-down PMF-derived fibroblasts. Images A and B are the two PMF-derived fibroblasts, 
whereas the control is represented by normal bone marrow fibroblasts
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3.4 | Clinical evaluation of pulmonary hypertension 
in PMF patients
After showing that PMF-derived fibroblasts have homing potential 
in the lung tissue, with possibly subsequent altering of the local 
mechanics, we assessed pulmonary hypertension in PMF patients 
by echocardiography (Figure 6A-I). When assessing pulmonary 
hypertension in PMF patients, we used a small cohort of patients 
(n = 5) for a preliminary proof-of-concept study. The link between 
patient characteristics, data on age, disease status or comorbidities 
F I G U R E  3   A, RT-PCR shows that myelofibrosis-derived fibroblasts, acting as cancer-associated fibroblasts, are highly dependent on 
TGFBR1, with a possible compensatory down-regulation of TGFBR2. B, Western blotting shows that myelofibrosis-derived fibroblasts, 
acting as cancer-associated fibroblasts, are highly dependent on TGFBR1, with a possible compensatory down-regulation of TGFBR2
F I G U R E  4   A, RT-PCR shows the role of mechanical stress is shown on PMF-derived fibroblasts. B, Western blotting data at 6 hours show 
the role of mechanical stress is shown on PMF-derived fibroblasts. C, Western blotting data at 24 hours show the role of mechanical stress 
is shown on PMF-derived fibroblasts
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and development of pulmonary hypertension is elaborated in the 
discussions section of the article. Peak tricuspid velocity (TRV) is 
depicted by the apical 4-chamber (A4C) view—CW Doppler. The 
peak velocity is 4.3 m/s. A TRV > 2.8 m/s is considered abnormal 
(Figure 6A). Pulmonary artery (PA) diameter is shown in Figure 6B, 
with a parasternal short-axis (PSAX) view—2D image. PA dimension 
is measured in end-diastole halfway between the pulmonary valve 
and bifurcation of main PA. PA diameter is 29 mm. A diameter of 
>25 mm is considered abnormal. Figure 6C depicts the early diastolic 
PR velocity PSAX-CW Doppler measurement through the pulmo-
nary valve in line with the PR jet. The peak (early/beginning of di-
astole) PR velocity value is measured. An early PR velocity >2.2 m/s 
is considered a marker of raised mean PAP. Right atrial (RA) area is 
presented in Figure 6D. The RA from the plane of the tricuspid valve 
F I G U R E  5   GFP-positive PMF-derived fibroblasts in the lungs (A) and bone marrow (B) of the nude mice using confocal microscopy
A B
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annulus along the interatrial septum, superior and lateral walls of 
RA. RA area is 36 cm2. RA area >18 cm2 is considered abnormal, a 
sign of pulmonary hypertension. RV/LV basal diameter ratio is pre-
sented in Figure 6E. This is measured from the standard A4C view 
without foreshortening. Measurement is taken at end-diastole. Ratio 
of >1 measured at end-diastole suggests RV dilatation (47.9/44.9). 
Figure 6F presents right ventricle (RV) dimensions. Basal RV diam-
eter is measured at the maximal transverse diameter in the basal one 
third of the RV. RVD2 > 41 mm is abnormal. RVD1: Mid RV diameter 
is measured at the level of the LV papillary muscles. RVD1 > 35 mm 
is abnormal. Figure 6G presents the RV pulsed tissue Doppler S wave 
(S′) velocity. PW tissue Doppler S wave measurement is taken at the 
lateral tricuspid annulus in systole. S′ wave velocity <9.5 cm/s indi-
cates RV systolic dysfunction. Figure 6H presents the tricuspid an-
nular plane systolic excursion (TAPSE). The excursion of the lateral 
tricuspid annulus is measured by M-mode between end-diastole 
and peak systole for a measure of longitudinal RV systolic func-
tion. TAPSE < 1.7 cm is highly suggestive of RV systolic dysfunc-
tion. Finally, Figure 6I shows the inferior vena cava diameter (IVC) 
Subcostal (2D M-mode). The diameter is measured perpendicular to 
the IVC long axis, 1 cm from the RA junction at end expiration. The 
IVC diameter >21 mm with decreased inspiratory collapse (<50% 
with a sniff or <20% with quiet respiration) is considered abnormal.
4  | DISCUSSIONS
TGF-β plays a major role in the biology of primary myelofibrosis, is 
being secreted by the malignant megakaryocytes and is likely fur-
ther affecting the bone marrow microenvironment.[12,40] TGF-β 
is a cytokine secreted in 3 isoforms: TGF-β1, TGF-β2 and TGF-β3, 
out of which TGF-β1 is the most abundant.[41,42] TGF-β1 is initially 
secreted in a latent form and further activated by reactive oxy-
gen species, as well as various proteases such as plasmin, integrins 
and trombospondin-1, and binds to two types of receptors: type I 
(TGFβR1) and type II (TGFβR2).[43] Initially, TGF-β1 binds to TGFβR2; 
then, TGFβR2 stimulates the protein kinase activity of TGFβR1 by re-
cruiting, binding and transphosphorylating it[44] (Figure 7). Further 
on, the transcription factors Smad2/3 are recruited and phosphoryl-
ated, which bind next to Smad4 and translocate in the nucleus where 
they interact with coactivators (as are CBP and p300), co-repressors 
(as are c-Ski, SnoN or TGIF) and transcription factors (as are Runx1 
or E2F), thus regulating the transcription of TGF-β-responsive genes.
[44] Smad phosphorylation was linked to bone marrow physiology 
by Lee et al,[45] who showed that BMP signalling through both 
Smad and p38 mitogen-activated protein kinase (MAPK) modulates 
the differentiation of mesenchymal stem cells in the bone marrow 
microenvironment. Cell shape and cytoskeleton micromechanics 
are altered by Smad protein phosphorylation in the bone marrow 
embryology via RhoA/ROCK-mediated tension generated by BMP-
induced signalling.[46] Other groups have looked at the essential 
interplay between biochemical and mechanical cues in cell differ-
entiation and as micromechanics plays key roles in both the normal 
physiology and embryology.[47] Our hypothesis was that mechani-
cal stress might modulate the progression of primary myelofibrosis 
by targeting TGF-β pathways in the bone marrow microenvironment.
Our results show an increase in collagen III, collagen I and al-
pha-SMA fold change at 24 hours when compared to 6 hours in 
PMF-derived fibroblasts blank vector. The same is seen in MF fi-
broblasts TGFBR2 KD (except for alpha-SMA expression in PMF 
fibroblasts blank vector). In contrast, PMF fibroblasts TGFBR1 KD 
presented a decrease in COL3, COL1 and alpha-SMA fold change at 
24 hours compared to 6 hours, showing the importance of TGFBR1, 
but not TGFBR2 in mechanical stress signalling in PMF fibroblasts. 
A possible explanation for these findings could be the exhaustion 
of fibroblasts when TGFBR1 signalling is down-regulated. It should 
be mentioned that this effect takes place although a cross-reactiv-
ity between TGFBR1 and TGFBR2 has been observed, although not 
at the same magnitude. Another point to take into consideration is 
the higher starting expression of TGFBR1 compared with TGFBR2 
in the primary fibroblasts, which can be observed further down the 
line in fibroblasts transfected with blank vector (data not shown). 
In conclusion, TGFBR1 has a greater drop in expression considering 
absolute values compared with TGFBR2, which argues in favour of 
the importance of TGFBR1 in mechanical stress response.
We also assessed collagen I and III secretion for the TGFβR1 
knock-down cells and found an important decrease in synthesis, 
both at the 6 and 24 hours following the exposure to micromechan-
ical stress. Interestingly, the secretion of both collagen I and III at 
24 hours was lower than the one at 6 hours, which suggests that the 
mechanism of synthesis was exhausted over time. In addition, the 
secretion of alpha-SMA was higher in TGF-β.
R1 knock-down cells at 6 hours, data not confirmed in any of 
the other cell lines, which suggests that the loss of TGFβR1 en-
abled a mechanism of secretion for alpha-SMA triggered by me-
chanical stress. However, this mechanism also was exhausted 
after 24 hours, as it was previously shown that the secretion of al-
pha-SMA decreased close to zero.[48-50] For TGFBR2 knock-down 
cells, collagen I and III were less expressed at 6 hours, in compar-
ison with the wild-type cells. However, the secretion of collagen 
I at 24 hours had the highest level of the 3 cell lines. Comparing 
the data from all 3 cell lines, if mechanical stress stimulates fi-
broblasts through this pathway, it suggests the activation of the 
TGFBR1 occurs through an alternative, more potent co-receptor. 
The secretion of alpha-SMA was close to undetectable at 6 hours 
but increased at 24 hours.
Cancer-associated fibroblasts are known and described to pro-
mote tumour progression and invasion but are reported to lack any 
potential to invade surrounding tissues themselves.[51-54] Still, our 
results show that PMF-derived fibroblasts, acting as cancer-asso-
ciated fibroblasts, if brought to the systemic blood flow, have the 
ability of ‘homing’ in the bone marrow and extramedullary site of 
haematopoiesis, including the lung. Lefrancais et al have shown that 
the lung is a site for platelet biogenesis and haematopoiesis.[55] We 
show that such fibroblasts, once they migrate into the hematopoietic 
organ, may it be the bone marrow or an extramedullary site, may be 
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activated and local mechanical pressure increases, thus promoting 
PMF. We indeed showed that micromechanics is altered in the bone 
marrow, not bringing forward any evidence for the same process oc-
curring in the lung tissue. Still, clinical data have shown that PMF 
patients do indeed experience pulmonary hypertension,[56-58] as 
did our patient cohort, according to international echocardiography 
guidelines.[59]
When assessing pulmonary hypertension in PMF patients, 
we used a small cohort as a proof-of-concept preliminary study. 
Still, the link between hypertension in the lung parenchyma and 
PMF was just published in April 2020 by the Lopez-Mattei and 
Verstovsek et al, using a 143 cohort of PMF patients.[60] They 
used echocardiogram and proved that 14% of patients had echo-
cardiographic findings consistent with PH. Older age, male gender, 
hypertension, hyperlipidemia, coronary artery disease, dyspnoea, 
haematocrit, brain natriuretic peptide (BNP) and N-terminal pro-
hormone BNP (NT-pro-BNP) were significantly different between 
those without and those with pulmonary hypertension (P < 0.05). 
NT-pro-BNP was a significant clinical predictor of hypertension of 
the lung parenchyma (P = 0.006). Pulmonary hypertension in MF is 
lower than previously hypothesized, but many patients had cardiac 
comorbidities.
Even if further studies, both in the pre-clinical setting and in the 
clinical data, must validate or invalidate our statement, we hypoth-
esize that PMF-derived fibroblasts have the potential to migrate in 
the lung parenchyma and change the local microenvironment, alter-
ing with the local micromechanics in order to promote disease pro-
gression and promote extramedullary haematopoiesis.
A major weakness of our study is that we used only a single-cell 
in vitro analysis system—the PMF-derived fibroblasts. These fibro-
blasts are not part of the neoplastic clone and are stimulated by ma-
lignant myeloid progenitors to proliferate and produce extracellular 
matrix, proven by Fialkow et al,[61] by Ciurea et al,[12] and by our 
group recently.[16] Thus, one might consider that the influence of 
mechanical stress on collagen synthesis might be linked to general fi-
broblast biology, rather than PMF. The same micromechanical stress 
might also act on malignant myeloid progenitors and their cytoplas-
mic protrusions that extend to the bone marrow. PMF basic biology 
should thus be investigated by using at least a co-culture system of 
fibroblasts and their interaction with hematopoietic progenitors. 
The co-culture is the next step in our research, as we aimed to un-
derstand each individual cell in the bone marrow microenvironment, 
this manuscript being of interest especially from a basic fibroblast 
biology standpoint.
5  | CONCLUSION
In conclusion, our data suggest that mechanical stress does indeed 
stimulate the collagen synthesis by the fibroblasts in patients with 
myelofibrosis. Further studies are nevertheless needed to elucidate 
the exact pathway or pathways through which it acts, as our studies 
suggest that it is the mechanism does not follow the TGF-β path-
way completely and other downstream pathways should be investi-
gated in the future, such as MAPK, ROCK or retinoic acid-mediated 
pathways.
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